Canadian grants & funding programs

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-NNN, the R61/R33 option).

United States

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

United States

Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and pilot test the navigator models ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the personalized match to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes.This FOA is published in parallel to a companion R01 (Currently Temp-11229)

United States

NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)

The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty conducting research that advances the mission of NIA. This three-year award provides protected time through salary and research support and is targeted at applicants who plan to start a tenure-track faculty position within a year of the award.

United States

Population Dynamics Centers Research Infrastructure Program FY 2024 (P2C Clinical Trial Not Allowed)

The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

United States

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigans National Addiction and HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Researchs (ICPSR) website.

United States

Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on ontogeny and development of pediatric immune system, from birth, transitioning into adolescence and adulthood with focus impact during pregnancy and post-natal period.

United States

Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).

United States

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.

United States

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01 Clinical Trial Required)

This NIDDK Funding Opportunity Announcement will support pilot and feasibility trials to test interventions that involve screening for and addressing adverse social determinants of health (SDoH), also called social risks, during a health care visit. Patients endorsed social needs could be addressed by appropriately referring/navigating patients or caregivers to resources that address these issues at social service organizations located externally or co-located in the healthcare system. The trials will determine 1) feasibility and acceptability of screening for social risks, identifying social needs and implementing referral service linkages (e.g., addressing transportation and housing needs, food insecurity, etc.) within the context of a healthcare visit, and 2) preliminary signals of the interventions impact on both the social risk/need(s) and NIDDK disease outcomes. Preliminary data regarding intervention efficacy are not required. The proposed pilot and feasibility clinical trials should lay the foundation for larger clinical trials to integrate social care and medical care and improve health outcomes related to the prevention and/or treatment of diseases within the mission of NIDDK. It is expected that these pilot studies will begin to delineate promising practices for future equitable and effective real world implementation of social and medical care integration. The overarching goal of this FOA is to develop pragmatic approaches that can be used in health care settings to reduce health disparities in diseases within the mission of NIDDK and achieve health equity, especially among individuals from racial and ethnic minority groups, rural populations, sexual and gender minority groups, and other socioeconomically disadvantaged and medically underserved communities.

United States

NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54Specialized Centercooperative agreements thatsupportlarge-scale, complex research projects with multiple highly integrated components focused onacommon research question relevant to Alzheimers disease (AD) andAlzheimers disease-related dementias (ADRD).It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium ofinstitutions,andwill address one or moreAD/ADRD implementation research milestonessupporting theresearch goals of theNational Plan to Address Alzheimers and Related Dementias.

United States

Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional)

The blood brain barrier (BBB) is a target of both the HIV virus and substances of abuse. It is a site of entry for HIV infected monocytes and macrophages that can traverse the BBB either paracellularly or transcellularly. HIV viral proteins can also attack astrocytes and tight junctions of BBB directly and compromise its integrity, resulting in the crossing of the virus, as well as abused substances, into the brain. Meanwhile, many substances of abuse cause BBB dysfunction. Because BBB integrity regulates both substances and virus levels in the brain, it is critical to establish the mechanisms by which HIV infection, in combination with substances of abuse, affect BBB function and integrity and their consequences. The purpose of this initiative is to support innovative research that elucidates the roles of HIV and addictive substances in the pathology of BBB. This FOA encourages studies to expand the current understanding of the basic molecular mechanisms underlying virus mobilization across BBB, and pathology of BBB in HIV infection and substance use disorders (SUD). In addition, studies are encouraged to develop and test novel BBB models to assess the delivery of pharmacological and immunotherapies to treat HIV infection and SUD, and to suppress HIV replication in CNS.

United States

NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) allows for renewal and competitive revision applications, and their resubmissions, for funded U24?Research Resource/Infrastructure?applications?that?support?large-scale, complex research programs focused on?Alzheimers disease (AD) and?Alzheimers disease-related dementias (ADRD).?It is anticipated that such programs will likely involve a team of investigators within a single institution or a consortium of?institutions?and?align with one or more?AD/ADRD implementation research milestones?supporting the?research goals of the??National Plan to Address Alzheimers and Related Dementias.

United States

NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for awarded U01 research project cooperative agreements focused on aging research.

United States

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (see RFA-HL-22-011).

United States

NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed

NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed Re-Issue

United States

NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)

The purpose of the NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence.

United States

NIMH Instrumentation Program (S10 Clinical Trial Not Allowed)

Reissue of RFA-MH-20-555. The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or a group of components to create an instrument that is not commercially available. Examples of instruments that might be submitted under this Funding Opportunity Announcement (FOA) include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers.

United States

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for the proposed research.

United States

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

United States

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

United States

NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

United States

NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are encouraged to work with their institutions to apply for support under this program eligible to apply. Investigators from categories A and B are particularly encouraged to work with their institutions to apply

United States

NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIAID R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the areas of biomedical, behavioral and clinical research, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development Research Experiences Mentoring Activities

United States

BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Basic Experimental Studies with Humans Required)

This FOA will support integrated, interdisciplinary research teams that focus on examining dynamic circuit functions related to behavior, using advanced and innovative technologies. The FOA will support programs with a necessarily-synergistic, team science approach. Awards will be made for 5 years, with a possibility of one competing renewal. Applications should focus on overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should aim to understand these circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches and experimental design guided by specified theoretical constructs, are encouraged to employ quantitative, mechanistic and predictive models where appropriate. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. Applications will be required to manage their data and analysis methods in a framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development.

United States

NIAID Research Education Program (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this National Institute of Allergy and infectious Diseases (NIAID) R25 program is to support educational activities that complement and/or enhance the training of a diverse workforce to meet the nations biomedical, behavioral and clinical research needs of NIAID mission areas.

United States

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)

NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program.

United States

NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)

The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research proposals should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources. Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus.

United States

NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)

The NIAID New Innovator Award supports a postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.

United States

NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, has annual direct costs equal to or greater than $500,000, that is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of $700,000 or more may also be a criteria for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application.

United States

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.

United States

OCI - Communitech AVIN ($50K; Q3 2020)

33% funding for product development, prototype creation, and market traction.

A funding program that provides financial assistance to small and medium-sized enterprises (SMEs) in Ontario to help them develop innovative technologies and products related to advanced vehicles. The Communitech AVIN program is administered by Communitech, a non-profit organization that supports the growth and development of technology companies in the Waterloo Region..

Ontario

NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)

The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).

United States

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)

NEPS Concept # 1875 This FOA invites R01 applications?to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to prevent, reduce, or eliminate racial or ethnic disparities in substance use and addiction, thereby advancing health equity. Community engaged research can facilitate rapid advances in this scientific area by ensuring relevant research questions with immediate applicability. As such, applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the community. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing racial or ethnic disparities and inequities in substance misuse. Research areas of interest will reflect community priorities and include etiology, prevention, health services research (including dissemination and implementation research), clinical neuroscience, medical consequences, and treatment and intervention development research.

United States

OCI - ENCQOR 5G ($50K; Q2 2021)

50% funding for 5G technology development, testing, and validation projects.

A funding program that provides financial assistance to small and medium-sized enterprises (SMEs) in Ontario to help them develop innovative technologies and products related to 5G networks. The ENCQOR 5G program is part of the ENCQOR (Evolution of Networked Services through a Corridor in Quebec and Ontario for Research and Innovation) initiative, which aims to support the development and deployment of advanced digital infrastructure in Ontario and Quebec..

Ontario

NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

United States

BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)

Reissue of RFA-NS-22-011 to comply with DMSP. No additional receipt dates added. This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.

United States

NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.

United States

NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)

The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.

United States

Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)

This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to develop novel tools and devices to improve handling of laboratory animals, to ease the management of animal facilities, and to enhance experiments which use animal models. The intent is to facilitate the design, implementation, and creation of tools and devices to directly benefit the welfare of research animals, and to advance equipment to improve infrastructure and environmental conditions of animal facilities that support biomedical and bio-behavioral research.

United States

Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)

This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects to develop novel tools and devices to improve handling of laboratory animals, to ease the management of animal facilities, and to enhance experiments which use animal models. The intent is to facilitate the design, implementation, and creation of tools and devices to directly benefit the welfare of research animals, and to advance equipment to improve infrastructure and environmental conditions of animal facilities that support biomedical and bio-behavioral research.

United States

NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to seek UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial.

United States

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and cost-effectiveness research (Stages IV/V).

United States

Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)

The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

United States

BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed)

This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals. This FOA is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. This will support iterative improvement of molecular payloads capable of monitoring and manipulating neural cell activity and that can be delivered to specific brain cell types using targeting technologies.

United States

BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

Reissue of RFA-MH-22-220 to comply with DMSP. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN Initiative. Other informatics programs include developing data standards that are needed to describe the new experiments that are being created by or used in the BRAIN Initiative ( RFA-MH-19-146 ), and creating the data infrastructures that will house the data from multiple experimental groups ( RFA-MH-19-145 ). Each of the programs is aimed at building an infrastructure that is used by a particular sub-domain of experimentalists rather than building a single all-encompassing informatics infrastructure now. Building the infrastructure one experimental area at a time will ensure that the infrastructure is immediately useful to components of the research community. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope.

United States

Notice of Intent to Publish a Notice of Funding Opportunity for the HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain Program Resource and Data Center (U24 Clinical Trial Not Allowed)

As part of the NIHÔř?sÔř?Helping to End Addiction Long-term (HEAL) initiative, theÔř?Eunice Kennedy ShriverÔř?National Institute of Child Health and Human Development and participating NIH Institutes and Centers (ICs)Ôř?intend to publish a Notice of Funding Opportunity (NOFO) to support research that aligns with one of the research goals of the NIH HEAL Initiative toÔř?support new clinical trial programs and the expansion of existing programs to evaluate innovative therapies for pain management.Ôř?The HEAL KIDS (Knowledge, Innovation and Discovery Studies) PainÔř?program will include interrelated programs addressing critical needs in pediatric pain research. This Notice of Intent to PublishÔř?announces plans to support the HEAL KIDS Pain Resource and Data Center (RDC) which will provide the following: leadership in data curation and data harmonization; leveraging relevant data standards; administrative and logistical support including oversight of NIH HEAL-related requirements; and coordination of shared research-related resources for the HEAL KIDS Pain research activities and HEAL-compliant data registries.Ôř?. Ôř? NICHD intends to utilize a cooperative agreement activity code (U24) for this NOFO. The HEAL KIDS Pain RDC NOFOÔř?is anticipated to publish in Summer 2023 with an expected application due date in Fall 2023. Anticipated details of the planned HEAL KIDS Pain RDC NOFO are provided below.

United States

Notice of Intent to Publish a Notice of Funding Opportunity for Network of Genomics-Enabled Learning Health Systems (gLHS) Ôř? Clinical Sites (U01 Clinical Trial Required)

The NHGRI intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to support a network of genomic-enabled learning health systems (gLHS). These health systems will identify and improve approaches for clinical integration of genomic information in a virtuous cycle of implementation, assessment, refinement, and re-implementation. Specifically, this initiative would: 1) support 4-6 established or emerging gLHS clinical sites to share their genomic medicine implementation practices and identify those most suitable for cross-network implementation; 2) use these practices to conduct 2-4 network-wide pilot implementation projects and evaluate their impact; and 3) develop and refine successful gLHS implementation strategies as resources that can be broadly shared and adopted, including in resource-limited settings.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects, and to allow potential applicants with relevant expertise and insights to consider applying for this new NOFO.. The NOFO is expected to be published in late summer 2023 with an expected application due date in fall 2023.. This NOFO will utilize the U01 activity code; clinical trial is required. Details of the planned NOFO are provided below.

United States